HUP0301422A2 - Ösztrogén hatású szereket tartalmazó gyógyászati készítmények - Google Patents

Ösztrogén hatású szereket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0301422A2
HUP0301422A2 HU0301422A HUP0301422A HUP0301422A2 HU P0301422 A2 HUP0301422 A2 HU P0301422A2 HU 0301422 A HU0301422 A HU 0301422A HU P0301422 A HUP0301422 A HU P0301422A HU P0301422 A2 HUP0301422 A2 HU P0301422A2
Authority
HU
Hungary
Prior art keywords
group
hydrogen atom
alkyl
general formula
ethers
Prior art date
Application number
HU0301422A
Other languages
English (en)
Inventor
Eric Joel Benjamin
Wendy Ann Dulin
Jiwaji Gulabrao Suryawanshi
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0301422A2 publication Critical patent/HUP0301422A2/hu
Publication of HUP0301422A3 publication Critical patent/HUP0301422A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány új gyógyszerészeti hordozó- vagy segédanyagrendszerre ésorális gyógyászati készítményekre vonatkozik, amelyek hatóanyagkéntraloxifent, amoxifent, droloxifent, arzoxifent vagy CP 336156-ot vagyezek analógjait vagy (I) vagy (II) általános képletű vegyületeket - aképletekben Z jelentése (a), (b) vagy (c) általános képletű csoport,ahol R1 jelentése hidrogénatom, hidroxilcsoport vagy annak észtereivagy alkil-éterei, benzoil-oxi-csoport vagy halogénatom vagyhalogénezett éterek; R2, R3, R4, R5 és R6 jelentése hidrogénatom,hidroxilcsoport vagy annak és észterei vagy alkil-éterei, halogénatom,vagy halogénezett éterek, cianocsoport, alkilcsoport vagy trifluor-metil-csoport, azzal a megkötéssel, hogy amikor R1 jelentésehidrogénatom, R2 jelentése hidroxilcsoporttól eltérő; X jelentésehidrogénatom, alkilcsoport, cianocsoport, nitrocsoport, tritfluor-metil-csoport vagy halogénatom; n értéke 1, vagy 3; Y jelentése (d)általános képletű csoport, ahol R7 és R8 elentése hidrogénatom, 1-6szénatomos alkilcsoport vagy fenilcsoport, vagy együtt adott esetbenhelyettesített nitrogéntartalmú gyűrűt alkotnak - vagy a vegyületekgyógyászatilag elfogadható sóját és gyógyszerészeti töltőanyagok,csúsztatóanyagok, kenőanyagok, nedvesítőszerek és antioxidánsok közülválasztott segédanyagot tartalmaznak. Ó
HU0301422A 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents HUP0301422A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21619200P 2000-07-06 2000-07-06
PCT/US2001/020993 WO2002003987A2 (en) 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents

Publications (2)

Publication Number Publication Date
HUP0301422A2 true HUP0301422A2 (hu) 2003-09-29
HUP0301422A3 HUP0301422A3 (en) 2006-07-28

Family

ID=22806095

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301422A HUP0301422A3 (en) 2000-07-06 2001-06-29 Pharmaceutical compositions of estrogenic agents

Country Status (26)

Country Link
US (2) US20020031548A1 (hu)
EP (1) EP1309327B1 (hu)
JP (1) JP2004502733A (hu)
KR (2) KR100862174B1 (hu)
CN (2) CN1450895A (hu)
AR (1) AR029538A1 (hu)
AT (1) ATE453391T1 (hu)
AU (2) AU7174101A (hu)
BR (1) BR0112242A (hu)
CA (1) CA2415058A1 (hu)
CY (1) CY1109915T1 (hu)
DE (1) DE60140945D1 (hu)
DK (1) DK1309327T3 (hu)
EA (1) EA006386B1 (hu)
ES (1) ES2336304T3 (hu)
HU (1) HUP0301422A3 (hu)
IL (2) IL153647A0 (hu)
MX (1) MXPA02012891A (hu)
NO (1) NO20030030L (hu)
NZ (1) NZ523330A (hu)
PL (1) PL204866B1 (hu)
PT (1) PT1309327E (hu)
SI (1) SI1309327T1 (hu)
TW (1) TWI294777B (hu)
WO (1) WO2002003987A2 (hu)
ZA (1) ZA200301004B (hu)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL366453A1 (en) * 2001-05-01 2005-02-07 Pfizer Products Inc. Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency
RU2355397C2 (ru) * 2002-06-13 2009-05-20 Уайт Режимы лечения базедоксифеном
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
CN1929835A (zh) * 2004-01-13 2007-03-14 惠氏公司 芳香酶抑制剂治疗－相关的骨质疏松症的治疗
TW200536845A (en) * 2004-04-07 2005-11-16 Wyeth Corp Crystalline polymorph of bazedoxifene acetate
AR048527A1 (es) 2004-04-07 2006-05-03 Wyeth Corp Variedades cristalinas de acetato de bazedoxifeno
CA2561124A1 (en) * 2004-04-08 2005-10-27 Wyeth Bazedoxifene acetate solid dispersion formulations
BRPI0509385A (pt) * 2004-04-08 2007-09-18 Wyeth Corp composto, composição, métodos de preparar o sal, ea dispensão sólida, de tratar um mamìfero tendo uma doença ou sìndrome associadas com a deficiência de estrogênio ou excesso de estrogênio, uma doença ou distúrbio associados com a proliferação ou desenvolvimento anormal dos tecidos endometriais, de tratar cáncer de mama em um mamìfero, e uma mulher pós-menopáusica quanto a um ou mais distúrbios vasomotores, de reduzir colesterol, e de inibir perda óssea em um mamìfero, dispersão sólida, e, uso de um composto
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN100358517C (zh) * 2004-09-28 2008-01-02 马晶 一种枸橼酸他莫昔芬口腔崩解片及其制备方法
EP1787642A1 (en) * 2004-11-10 2007-05-23 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EP1729735B1 (en) * 2004-11-10 2007-06-27 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
EP1863464B1 (en) * 2005-03-31 2009-11-11 Wyeth O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof
TW200738283A (en) * 2005-06-29 2007-10-16 Wyeth Corp Formulations of conjugated estrogens and bazedoxifene
AR056471A1 (es) * 2005-08-24 2007-10-10 Wyeth Corp Formulaciones de acetato de bazedoxifeno
AU2012275036B2 (en) * 2005-08-24 2016-05-19 Wyeth Llc Bazedoxifene acetate formulations and manufacturing process thereof
TW200836774A (en) * 2007-02-01 2008-09-16 Takeda Pharmaceutical Solid preparation
CA2696984C (en) * 2007-10-16 2013-04-23 Pharmathen S.A. Improved pharmaceutical composition containing a selective estrogen receptor modulator and method for the preparation thereof
EP2271320A4 (en) * 2008-04-02 2011-05-18 Reddys Lab Ltd Dr PHARMACEUTICAL RALOXIFY FORMULATIONS
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2011000581A2 (en) 2009-07-02 2011-01-06 Synthon B.V. Raloxifene composition
AR078785A1 (es) 2009-10-27 2011-11-30 Wyeth Llc Formulaciones de bazedoxifeno con antioxidantes
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
CN104519874B (zh) 2012-06-05 2018-08-03 武田药品工业株式会社 固体制剂
WO2013182169A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
WO2013182170A1 (en) 2012-06-07 2013-12-12 Zentiva, K. S. Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate
CN103006570B (zh) * 2012-10-08 2013-12-25 孙维会 一种阿佐昔芬速释微丸及其制备方法
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
LT3105226T (lt) 2014-02-13 2019-11-11 Incyte Corp Ciklopropilaminai, kaip lsd1 inhibitoriai
CN103830197A (zh) * 2014-03-14 2014-06-04 崔书豪 一种盐酸雷洛昔芬分散片及其制备方法
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201642856A (zh) * 2015-04-02 2016-12-16 施萬生物製藥研發Ｉｐ有限責任公司 Ｍｕ類鴉片受體拮抗劑與類鴉片藥劑之組合劑型
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
SG10202001219UA (en) 2015-08-12 2020-03-30 Incyte Corp Salts of an lsd1 inhibitor
US11786471B2 (en) * 2016-07-11 2023-10-17 Wuhan Ll Science And Technology Development Co. Ltd. Complex disintegrant system for oral solid preparation and oral solid preparation comprising said complex disintegrant system
KR101683193B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
KR101683192B1 (ko) * 2016-10-20 2016-12-08 전남대학교산학협력단 비환원성 말단의 불포화형 만뉴론산 올리고당을 유효성분으로 포함하는 갱년기 증후군의 개선, 예방 또는 치료용 조성물
CN107951034B (zh) * 2017-12-01 2021-03-23 郑州拓洋生物工程有限公司 维生素泡腾制剂及其制备方法
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
RU2732291C1 (ru) * 2020-02-13 2020-09-15 Открытое акционерное общество "Фармстандарт-Лексредства" (ОАО "Фармстандарт-Лексредства") Лекарственный препарат на основе травы алтея лекарственного для лечения простудных и острых респираторных заболеваний

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3552727A (en) * 1968-09-18 1971-01-05 American Air Filter Co Gas scrubbing apparatus
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
JP3029742B2 (ja) * 1992-08-20 2000-04-04 株式会社東芝 画像補正装置
JPH0674903A (ja) * 1992-08-26 1994-03-18 Sumitomo Metal Ind Ltd 平板状被検出材の微小欠陥検出方法及び装置
FR2698788B1 (fr) 1992-12-09 1995-03-03 Union Pharma Scient Appl Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
US5342133A (en) * 1992-12-23 1994-08-30 Hewlett-Packard Company Paper moving system for a printer/plotter
US5332727A (en) * 1993-04-29 1994-07-26 Birkmayer U.S.A. Stable, ingestable and absorbable NADH and NADPH therapeutic compositions
CA2143263C (en) * 1994-03-02 2002-01-08 Kerry John Hartauer Orally administrable raloxifene formulations
US5478847A (en) * 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
US5811120A (en) 1994-03-02 1998-09-22 Eli Lilly And Company Solid orally administerable raloxifene hydrochloride pharmaceutical formulation
US5552412A (en) 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
SG90193A1 (en) * 1995-02-28 2002-07-23 Lilly Co Eli Benzothiophene compounds, intermediates, compositions, and methods
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5919800A (en) 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5880137A (en) * 1996-04-19 1999-03-09 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
US5780497A (en) 1996-04-19 1998-07-14 American Home Products Corporation 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents
TW397821B (en) * 1996-04-19 2000-07-11 American Home Produits Corp 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof
ATE206701T1 (de) * 1996-04-19 2001-10-15 American Home Prod Östrogene verbindungen
EP1777214A3 (en) 1997-10-15 2007-05-09 Wyeth Novel aryloxy-alkyl-dialkylamines
JP2002521322A (ja) * 1998-07-23 2002-07-16 ノボ ノルディスク アクティーゼルスカブ 安定な医薬製剤の製造のための湿式顆粒化方法

Also Published As

Publication number Publication date
ES2336304T3 (es) 2010-04-12
US7759386B2 (en) 2010-07-20
DK1309327T3 (da) 2010-04-26
EA200300122A1 (ru) 2003-06-26
SI1309327T1 (sl) 2010-03-31
EP1309327A2 (en) 2003-05-14
EA006386B1 (ru) 2005-12-29
WO2002003987A3 (en) 2002-07-11
NZ523330A (en) 2005-07-29
US20020031548A1 (en) 2002-03-14
PT1309327E (pt) 2010-02-23
AR029538A1 (es) 2003-07-02
JP2004502733A (ja) 2004-01-29
AU2001271741B2 (en) 2006-10-19
MXPA02012891A (es) 2003-10-24
PL204866B1 (pl) 2010-02-26
CN101416949A (zh) 2009-04-29
CY1109915T1 (el) 2014-09-10
KR20030023689A (ko) 2003-03-19
CN1450895A (zh) 2003-10-22
KR20070110454A (ko) 2007-11-16
KR100862174B1 (ko) 2008-10-09
TWI294777B (en) 2008-03-21
NO20030030D0 (no) 2003-01-03
ATE453391T1 (de) 2010-01-15
ZA200301004B (en) 2004-05-05
KR100894027B1 (ko) 2009-04-22
HUP0301422A3 (en) 2006-07-28
IL153647A0 (en) 2003-07-06
DE60140945D1 (de) 2010-02-11
IL153647A (en) 2011-03-31
BR0112242A (pt) 2003-06-24
US20080269198A1 (en) 2008-10-30
EP1309327B1 (en) 2009-12-30
PL365875A1 (en) 2005-01-10
AU7174101A (en) 2002-01-21
NO20030030L (no) 2003-03-03
WO2002003987A2 (en) 2002-01-17
CA2415058A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
HUP0301422A2 (hu) Ösztrogén hatású szereket tartalmazó gyógyászati készítmények
UY27384A1 (es) Analogos de prostaglandina
IS2598B (is) Þíenópýrimidíndíón og notkun þeirra í mótun sjálfnæmissjúkdóma
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
IL108602A0 (en) N-alkyl-2-substituted atp analogues, their preparation and pharmaceutical compositions containing them
HUP0100280A2 (hu) Pirrolo-, tieno-, furano- és pirazolo [3,4d] piridazonok, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények
AU4306796A (en) Novel 3,5-dioxo-(2h,4h)-1,2,4-triazine derivatives, their preparation and use as drugs
ZA200505273B (en) Novel compound
HUP0103096A2 (hu) 2-Fenil-1-[4-(2-amino-etoxi)-benzil]-indol-származékok és ösztrogének kombinációját tartalmazó gyógyszerkészítmények
ATE250622T1 (de) 4'-c-ethynyl-pyrimidine nukleoside
HUP9902454A2 (hu) Szubsztituált 1,2,3,4-tetrahidronaftalin-származékok, előállításuk és alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP0401235A2 (hu) 5-HT6 receptor affinitással rendelkező arilszulfonil-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
AR007108A1 (es) Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
RU2010154417A (ru) Комбинация частичного агониста никотиновых рецепторов и ингибитора ацетилхолинетеразы, содержащая ее фармацетическая композиция, и ее применение в лечении когнитивных расстройств
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HUP0104963A2 (hu) Bőrbetegségek kezelésére szolgáló készítmények
AR032066A1 (es) Agente para tratamiento terapeutico y profilactico del dolor neuropatico
HRP20070030T3 (en) Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them
HUP0401018A2 (hu) 2H-1-benzopirán-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények
HUP0002929A2 (hu) Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények
HUP0402341A2 (hu) Szubsztituált tiazol-2-ilaminokat tartalmazó készítmények rák kezelésére
ZA995321B (en) Indan-1-Ol compounds, a process for their preparation and pharmaceutical compositions containing them.
DE60220779D1 (de) Tetrahydropyridyl-alkyl-heterozykle, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die sie enthalten
HUP0104533A2 (hu) Új pirimidinszármazékok és eljárás ezek előállítására és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees